Histone deacetylase (HDAC) inhibitors modify transcription of selected genes and
eventually induce apoptosis. However, molecular mechanisms for their proapoptotic activity …

Histone deacetylase (HDAC) inhibitors augment ionizing radiation (IR)-induced apoptosis in
several cancer cells by undefined mechanism (s). We recently found that the HDAC …

Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents,
but some exhibit resistance mechanisms linked to anti-apoptotic Bcl-2 functions, such as …

Inhibitors of histone deacetylases (HDACIs) are a new generation of anticancer agents that
selectively kill tumor cells. However, the molecular basis for their tumor selectivity is not well …

Several histone deacetylase inhibitors (HDACi), which have recently entered early clinical
trials, exert their anticancer activity in part through the induction of apoptosis although the …

Histone deacetylase inhibitors (HDACi) can elicit a range of biological responses that
impede the growth and/or survival of tumor cells. Depending on the physiological context …

Histone deacetylase (HDAC) inhibitors have been shown to induce cell cycle arrest and
apoptosis in cancer cells. However, the mechanisms of HDAC inhibitor induced apoptosis …

BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically
inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities …

Histone acetylation marks have an important role in controlling gene expression and are
removed by histone deacetylases (HDACs). These marks are read by bromodomain and …

Histone deacetylase inhibitors (HDACis) inhibit tumor cell growth and survival, possibly
through their ability to regulate the expression of specific proliferative and/or apoptotic …